[go: up one dir, main page]

PE20080908A1 - Agonistas lxr para el tratamiento de osteoartritis - Google Patents

Agonistas lxr para el tratamiento de osteoartritis

Info

Publication number
PE20080908A1
PE20080908A1 PE2007001263A PE2007001263A PE20080908A1 PE 20080908 A1 PE20080908 A1 PE 20080908A1 PE 2007001263 A PE2007001263 A PE 2007001263A PE 2007001263 A PE2007001263 A PE 2007001263A PE 20080908 A1 PE20080908 A1 PE 20080908A1
Authority
PE
Peru
Prior art keywords
test compound
lxr
osteoarthritis
treatment
inhibits
Prior art date
Application number
PE2007001263A
Other languages
English (en)
Inventor
Sunil Nagpal
Zhiyong Yang
Elisabeth Morris
Vallie Edward R La
Lisa A Collins-Racie
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080908A1 publication Critical patent/PE20080908A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN COMPUESTO OXISTEROL SINTETICO O UN NO-OXISTEROL SINTETICO TAL COMO EL N-(2,2,2-TRIFLUOROETIL)-N-[4-(2,2,2-TRIFLUORO-1-HIDROXI-1-TRIFLUOROMETIL-1-ETIL)-FENIL]-BENCENOSULFONAMIDA, EL CUAL ES UTIL COMO COMPUESTO DE PRUEBA EN UN PROCEDIMIENTO PARA LA IDENTIFICACION DE UN LIGANDO DE LOS RECEPTORES X DEL HIGADO (LXR), DONDE DICHO PROCESO COMPRENDE: a) PROPORCIONAR UNA MUESTRA QUE CONTIENE UN LIGANDO LXR, b) CONTACTAR LA MUESTRA CON EL COMPUESTO DE PRUEBA Y c) DETERMINAR SI EL COMPUESTO DE PRUEBA INDUCE EXPRESION DE APOLIPOPROTEINA D, INHIBE LA ACTIVIDAD DE AGRECANASA, INHIBE LA ELABORACION DE CITOQUINAS PRO-INFLAMATORIAS O UNA COMBINACION DE ESTAS
PE2007001263A 2006-09-19 2007-09-19 Agonistas lxr para el tratamiento de osteoartritis PE20080908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84557606P 2006-09-19 2006-09-19

Publications (1)

Publication Number Publication Date
PE20080908A1 true PE20080908A1 (es) 2008-08-21

Family

ID=38828649

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001263A PE20080908A1 (es) 2006-09-19 2007-09-19 Agonistas lxr para el tratamiento de osteoartritis

Country Status (14)

Country Link
US (1) US20090012053A1 (es)
EP (1) EP2089009A2 (es)
JP (1) JP2010503730A (es)
CN (1) CN101547688A (es)
AR (1) AR062913A1 (es)
AU (1) AU2007297721A1 (es)
BR (1) BRPI0716833A2 (es)
CA (1) CA2662965A1 (es)
CL (1) CL2007002712A1 (es)
MX (1) MX2009002794A (es)
PA (1) PA8748501A1 (es)
PE (1) PE20080908A1 (es)
TW (1) TW200820978A (es)
WO (1) WO2008036239A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
BRPI1007896A2 (pt) * 2009-02-02 2016-02-16 Imperal Innovations Ltd métodos para diagnosticar insuficiência articular iminente
CN103063840A (zh) * 2011-10-18 2013-04-24 中国科学院武汉病毒研究所 一种细胞靶点肝x受体在制备治疗丙型肝炎病毒药物中的应用
JP6071608B2 (ja) * 2012-03-09 2017-02-01 新日鐵住金ステンレス株式会社 耐酸化性に優れたフェライト系ステンレス鋼板
KR20150040766A (ko) * 2013-10-07 2015-04-15 이화여자대학교 산학협력단 항염증 물질을 스크리닝하는 방법
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CN119868520B (zh) * 2025-01-08 2025-10-24 浙江大学 棕榈酰基转移酶zdhhc11在制备治疗骨关节炎药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US20020048572A1 (en) * 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
BR0215258A (pt) * 2001-12-21 2004-12-07 Pharmacia Corp Moduladores de receptor x de fìgado de tioéter aromático
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US20050123580A1 (en) * 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
CA2486651A1 (en) * 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
WO2004026816A1 (en) * 2002-09-17 2004-04-01 Pharmacia Corporation Aromatic liver x-receptor modulators
WO2004058175A2 (en) * 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US20050009837A1 (en) * 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
RU2006124843A (ru) * 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
US20060029685A1 (en) * 2004-07-30 2006-02-09 Henderson Todd R Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals
AR050279A1 (es) * 2004-08-03 2006-10-11 Wyeth Corp Indazoles como moduladores de lxr utiles en la preparacion de medicamentos pata el tratamiento de enfermedades cardiovasculares y mediadas por th1 y composiciones farmaceuticas que los contienen como principio activo.
AU2006218661A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver X receptor modilators
US9670244B2 (en) * 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway

Also Published As

Publication number Publication date
US20090012053A1 (en) 2009-01-08
WO2008036239A3 (en) 2008-10-30
CL2007002712A1 (es) 2008-05-16
PA8748501A1 (es) 2009-07-23
WO2008036239A2 (en) 2008-03-27
CA2662965A1 (en) 2008-03-27
CN101547688A (zh) 2009-09-30
AU2007297721A1 (en) 2008-03-27
TW200820978A (en) 2008-05-16
EP2089009A2 (en) 2009-08-19
JP2010503730A (ja) 2010-02-04
BRPI0716833A2 (pt) 2013-11-05
MX2009002794A (es) 2009-03-30
AR062913A1 (es) 2008-12-17

Similar Documents

Publication Publication Date Title
PE20080908A1 (es) Agonistas lxr para el tratamiento de osteoartritis
CL2007003793A1 (es) Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
MX2021001659A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
CL2012001429A1 (es) Dispositivo utilizado para el tratamiento de la rinitis por iluminacion bioestimulativa que comprende un par de led que contienen sondas para ser insertadas en las fosas nasales y una carcasa de soporte de sondas
ES2422556T3 (es) Tratamiento de hepatitis vírica
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
GT200500269A (es) Procedimiento
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
SV2009003289A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico para imagenes
CL2007001784A1 (es) Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado.
ES2531516T3 (es) Uso de escina
AR060440A1 (es) Agonistas receptores de eritropoietina
ES2601028T3 (es) Método de medición inmunológica para el precursor del péptido liberador de gastrina
AR076113A1 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
CL2008001829A1 (es) Uso de combinaciones de principios activos que contienen compuestos derivados de cetoenoles ciclicos y al menos un agonista o antagonista de receptores de acetilcolina para combatir insectos de la familia de las chinches.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
ES2572368T3 (es) Tratamiento de la artrosis
CL2007003422A1 (es) Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero.
EP4603937A4 (en) AUTONOMOUS RESEARCH METHOD AND COMPUTER DEVICE FOR IMPLEMENTING SAID METHOD
AR048943A1 (es) Metodo para mejorar el crecimiento de las plantas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal